OS Therapies (OSTX)
NYSE: OSTX
· Real-Time Price · USD
2.08
0.02 (0.97%)
At close: Aug 18, 2025, 10:56 AM
OS Therapies Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q1 2022 | Q4 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Mar 31, 2022 | Dec 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.21 | 18.48 |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -1.21 | -18.48 |
Operating Income | -5B | -2.97M | -2.44M | -779.8K | -630.23K | -1.16M | -622.21K | -1.52K | -1.05K | -1.74K | -889.39 | -1.27K |
Interest Income | 66K | n/a | n/a | 1.00 | n/a | n/a | 1.00 | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -3.88B | -2.99M | -2.88M | -1.56M | -1.46M | -1.46M | -1.97M | -2.51K | -1.85K | -2.55K | -1.36K | -2.36K |
Net Income | -3.88B | -2.99M | -2.88M | -1.56M | -1.46M | -1.46M | -1.97M | -2.51K | -1.85K | -2.55K | -1.36K | -2.36K |
Selling & General & Admin | 3.69B | 2.1M | 1.23M | 383.23K | 268.42K | 132.88K | 167.7K | 522.48 | 294.25 | 642.62 | 203.42 | 555.27 |
Research & Development | 1.31B | 870.47K | 1.21M | 396.57K | 361.81K | 1.02M | 454.5K | 992.90 | 753.78 | 1.1K | 684.76 | 692.97 |
Other Expenses | n/a | n/a | n/a | n/a | n/a | 5.15K | n/a | 0.00 | n/a | -0.00 | n/a | -0.00 |
Operating Expenses | 5B | 2.97M | 2.44M | 779.8K | 630.23K | 1.16M | 622.21K | 1.52K | 1.05K | 1.74K | 888.18 | 1.25K |
Interest Expense | n/a | 7.56K | 437.84K | 777.68K | 828.76K | 307.53K | 1.35M | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | -2.97M | 2.44M | 779.8K | 630.23K | 1.16M | 622.21K | 1.52K | 1.05K | 1.74K | 889.39 | 1.27K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 21.25M | 123.77M | 15.9M | 20.6M | 20.05M | 20.05M | 20.05M | 5.27M | 10.04M | 9.86M | 9.76M | 13.41M |
Shares Outstanding (Diluted) | 21.25M | 123.77M | 15.9M | 20.6M | 20.05M | 20.05M | 23.1M | 5.34M | 10.21M | 9.98M | 9.98M | 13.41M |
EPS (Basic) | -0.18 | -0.04 | -0.18 | -0.08 | -0.07 | -0.07 | -0.1 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
EPS (Diluted) | -0.18 | -0.04 | -0.18 | -0.08 | -0.07 | -0.07 | -0.1 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
EBITDA | -5B | -2.98M | -2.44M | -779.1K | -629.54K | -1.16M | -618.89K | -1.51K | -1.05K | -1.74K | -889.19 | -1.27K |
EBIT | n/a | -2.98M | -2.44M | -779.8K | -630.23K | -1.16M | -622.21K | -1.52K | -1.05K | -1.74K | -889.39 | -1.27K |
Depreciation & Amortization | n/a | -1.39K | n/a | 695.00 | 695.00 | n/a | 3.31K | 0.81 | 0.10 | 0.20 | 0.20 | 0.20 |